Theoretically, reduced PARP1 expression decreases PARPi sensitivity by reducing PARPi binding sites, as has been shown in the PDX model of breast cancer, and in vitro studies in human ovarian cancer tumor lines have shown that PARP1 deficiency leads to PARPi acquired resistance [37, 57, 78]. Here, PARP1 is linked to breast carcinoma.